Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17115832 | 0.85 | CYP2D6 (0.43) | CYP2D6CYP1A2CYP2A6ADRA2AADRA1A | |
| SCHEMBL31119095 | 0.84 | CYP2D6 (0.43) | CYP2D6CYP1A2ADRA2AADRA1AMEN1 | |
| SCHEMBL20238552 | 0.84 | CYP2D6 (0.53) | CYP2D6ADRA2AADRA1AMEN1MAPK1 | |
| SCHEMBL2823287 | 0.84 | CYP2D6 (0.53) | CYP2D6ADRA2AADRA1AMEN1MAPK1 | |
| SCHEMBL31119047 | 0.84 | ADRA2A (0.49) | CYP2D6ADRA2AADRA1AMEN1MAPK1 | |
| SCHEMBL3702003 | 0.84 | CYP2D6 (0.53) | CYP2D6ADRA2AADRA1AMEN1MAPK1 | |
| SCHEMBL16960809 | 0.84 | CYP2D6 (0.43) | CYP2D6CYP1A2ADRA2AADRA1AMEN1 | |
| SCHEMBL25626349 | 0.84 | CYP2D6 (0.43) | CYP2D6CYP1A2ADRA2AADRA1AMEN1 | |
| SCHEMBL8241491 | 0.83 | CA12 (0.45) | CYP2D6CYP1A2CYP2A6ADRA2AADRA1A | |
| SCHEMBL31063437 | 0.83 | CA12 (0.45) | CYP2D6CYP1A2CYP2A6ADRA2AADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024148060-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| EP-3956320-B1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH INC (US) | 2023-11-29 | — | — | EP | disclosed |
| US-20230365588-A1 | DIOL DESYMMETRIZATION BY NUCLEOPHILIC AROMATIC SUBSTITUTION | AMGEN INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-11793771-B2 | Immunomodulator compounds | CHEMOCENTRYX, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11759458-B2 | Indane-amines as PD-L1 antagonists | CHEMOCENTRYX, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230183219-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| US-20230174521-A1 | NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230167131-A1 | HETEROCYCLIC PAD4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-06-01 | — | — | US | disclosed |
| WO-2023086539-A2 | BCAT2 INHIBITORS | AGIOS PHARMACEUTICALS, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20080058349-A1 | New Compounds 318 | ASTRAZENECA AB (SE) | 2008-03-06 | — | — | US | disclosed |
| US-20080051420-A1 | New Compounds 317 | ASTRAZENECA AB (SE) | 2008-02-28 | — | — | US | disclosed |
| US-20080051420-A1 | New Compounds 317 | ASTRAZENECA AB (SE) | 2008-02-28 | — | — | US | disclosed |
| US-20070299087-A1 | New Compounds 319 | ASTRAZENECA AB (SE) | 2007-12-27 | — | — | US | disclosed |
| US-20070299087-A1 | New Compounds 319 | ASTRAZENECA AB (SE) | 2007-12-27 | — | — | US | disclosed |
| WO-2007145569-A1 | AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA | ASTRAZENECA AB (SE) | 2007-12-21 | — | — | WO | disclosed |
| US-20070208049-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070149506-A1 | Azepine inhibitors of Janus kinases | INCYTE CORPORATION | 2007-06-28 | — | — | US | disclosed |
| US-20070149506-A1 | Azepine inhibitors of Janus kinases | INCYTE CORPORATION | 2007-06-28 | — | — | US | disclosed |
| WO-2004085408-A1 | 2, 3, 6-TRISUBSTITUTED-4-PYRIMIDONE DERIVATIVES | MITSUBISHI PHARMA CORPORATION (JP) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | MKNK2, MKRN3, DUS2 | CYP2D6 474/4885CYP1A2 74/4885CYP2A6 604/4885 |
| US-20070299087-A1 | New Compounds 319 | PSEN2, PSEN1, MAPT | CYP2D6 4190/4885CYP1A2 3794/4885CYP2A6 4017/4885 |
| US-20230183219-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM3, CHRM2, CHRM4 | CYP2D6 1390/4885CYP1A2 2589/4885CYP2A6 2261/4885 |
| US-11793771-B2 | Immunomodulator compounds | IL2, IL2RA, C3AR1 | CYP2D6 638/4885CYP1A2 926/4885CYP2A6 790/4885 |
| US-20080058349-A1 | New Compounds 318 | PSEN2, PSEN1, MAPT | CYP2D6 4314/4885CYP1A2 3831/4885CYP2A6 4168/4885 |
| US-20080051420-A1 | New Compounds 317 | PSEN2, PSEN1, MAPT | CYP2D6 4357/4885CYP1A2 3812/4885CYP2A6 4222/4885 |
| US-20230174521-A1 | NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | DGAT2, DGAT1, ACAT2 | CYP2D6 620/4885CYP1A2 299/4885CYP2A6 676/4885 |
| US-20230365588-A1 | DIOL DESYMMETRIZATION BY NUCLEOPHILIC AROMATIC SUBSTITUTION | MCL1, BAK1, BCL2A1 | CYP2D6 1853/4885CYP1A2 1593/4885CYP2A6 3440/4885 |
| US-20070208049-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | CYP2D6 790/4885CYP1A2 1189/4885CYP2A6 551/4885 |
| US-20230167131-A1 | HETEROCYCLIC PAD4 INHIBITORS | PADI4, PADI2, PADI6 | CYP2D6 460/4885CYP1A2 380/4885CYP2A6 775/4885 |
| US-11759458-B2 | Indane-amines as PD-L1 antagonists | CD274, PDCD1LG2, PDCD1 | CYP2D6 739/4885CYP1A2 489/4885CYP2A6 2409/4885 |
| US-20070149506-A1 | Azepine inhibitors of Janus kinases | JAK1, JAK3, JAK2 | CYP2D6 3832/4885CYP1A2 2692/4885CYP2A6 4021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.